Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 26715039)

Published in BMC Urol on December 30, 2015

Authors

Nandu D Dantanarayana¹, Tania Hossack², Paul Cozzi³, Andrew Brooks¹^,2, Howard Lau², Warick Delprado⁴, Manish I Patel⁵^,6

Author Affiliations

1: University of Sydney, Discipline of Surgery, Sydney, Australia.
2: Department of Urology, Westmead Hospital, Sydney, Australia.
3: St George Hospital, Sydney, Australia.
4: Douglass Hanley Moir Pathology, Sydney, Australia.
5: University of Sydney, Discipline of Surgery, Sydney, Australia. mpatel@med.usyd.edu.au.
6: Department of Urology, Westmead Hospital, Sydney, Australia. mpatel@med.usyd.edu.au.

Articles cited by this ↗

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet (2014) 11.01

Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate (2004) 4.02

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ (2013) 3.51

Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer (1993) 2.99

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

Screening for prostate cancer. Cochrane Database Syst Rev (2013) 2.29

The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol (2008) 1.93

Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer (2009) 1.89

A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med (2009) 1.74

International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer (2001) 1.59

Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology (2007) 1.20

Prostate cancer in elderly men. Rev Urol (2008) 1.19

Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology (2005) 1.05

Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer (2002) 0.95

Epstein criteria for insignificant prostate cancer. BJU Int (2011) 0.93

Articles by these authors ⇆

Acceptance of repeat transrectal ultrasonography guided prostate biopsies with local anaesthesia. BJU Int (2011) 0.75